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    Summary and Implications 
 African swine fever virus (ASFV) proteins were 
expressed in an alphavirus based replicon expression 
system.  Pigs vaccinated with the recombinant vectors 
developed ASFV-specific antibodies.  This is the first 
known use of this technology against ASFV. 
 
Introduction 
 African swine fever virus is the cause of acute 
hemorrhagic fever in swine.  The virus is endemic to Africa 
and parts of Eurasia.  ASFV represents a significant threat to 
the US swine industry as a foreign animal disease.  
Alphavirus-derived replicon particles (RP) are safe and 
effective vaccine vectors, and have recently been approved 
for use in swine by USDA. 
 
Materials and Methods 
 The ASFV p30 and p72 genes were cloned into the 
replicon DNA plasmid and confirmed intact by sequencing.  
A histidine tag sequence was added to the 3’ end of each 
gene for use in expression assays.  Replicon RNA was 
generated by in vitro transcription using T7 RNA 
polymerase.  RP were produced by co-electroporation of 
p30 and p72 replicon RNA and helper RNAs into Vero 
cells. The RP were harvested by affinity chromatography 
and titer was determined by immunofluorescence assay.  
Vero cells were infected with RP expressing either p30 or 
p72, and cell lysates were analyzed by Western blot using 
anti-histidine tag antibodies.  Young pigs (n=3) were 
vaccinated twice with a combination of RP expressing 
ASFV p30 or p72, and serum samples were analyzed for 
anti-ASFV response. 
 
Results and Discussion 
 Western blot confirmed that RP were capable of 
expressing ASFV p30 and p72 (Figure 1).  Western blot 
analysis of RP-vaccinated pig serum showed specific anti-
ASFV antibodies.  Future work will evaluate the ability of 
RP-based vaccine candidates to protect pigs in ASFV 
challenge studies. 
 
 
Figure 1.  Expression of ASFV p30 and p72 using RP. 
 
